# US 2004/0001830 A1 · Human tissue factor antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0001830 A1
- Document ID: US20040001830A1
- Status: Published application
- Kind: A1
- Application number: 10/261,706
- Filed: 2002-09-30
- Published: 2004-01-01
- Earliest claimed: 2001-10-02
- Inventors: Per-Ola Freskgaard; Jes Clausen Clausen; Brit Binow Sorensen; Marianne Kjalke
- Web page: https://patentgrep.com/patent/US20040001830A1

## CPC

- C07K 16/36: against blood coagulation factors
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to isolated fully human antibodies that immunoreacts with human tissue factor (TF) to inhibit the binding of coagulation factor VIIa (FVIIa).

## Claims

### Claim 1

An isolated human antibody, wherein said antibody immunoreacts with an epitope present on human tissue factor (TF).

### Claim 2 (depends on 1)

The isolated human antibody according to claim 1, wherein said antibody inhibits the binding of human coagulation factor VIIa to human TF.

### Claim 3 (depends on 1)

The isolated human antibody according to claim 1, wherein said antibody is a monoclonal antibody.

### Claim 4 (depends on 1)

The isolated human antibody according to claim 1, wherein said antibody is a recombinant antibody.

### Claim 5 (depends on 1)

The isolated human antibody according to claim 1, wherein said antibody is an Fab fragment.

### Claim 6 (depends on 1)

The isolated human antibody according to claim 1, wherein said antibody is an F(ab)2 fragment.

### Claim 7 (depends on 1)

The isolated human antibody according to claim 1, wherein said antibody is an F(ab′)2 fragment.

### Claim 8 (depends on 1)

The isolated human antibody according to claim 1, wherein said antibody is a single chain Fv fragment.

### Claim 9 (depends on 1)

The isolated human antibody according to claim 1, wherein said antibody has a Kd for binding to human TF within the range of 10−15-10−8 M.

### Claim 10 (depends on 9)

The isolated human antibody according to claim 9, wherein said antibody has a Kd for binding to human TF within the range of 10−15-10−10 M.

### Claim 11

A pharmaceutical composition comprising a therapeutically effective amount of a human antibody, wherein said antibody immunoreacts with an epitope present on human TF.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The pharmaceutical composition comprising a therapeutically effective amount of a human antibody, which immunoreacts with an epitope present on human TF, wherein said antibody is according to any one of the claims 1-10.

### Claim 13

A composition comprising a human antibody, which immunoreacts with an epitope present on human TF.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The composition comprising a human antibody, which immunoreacts with an epitope present on human TF, wherein said antibody is according to any one of the claims 1-10.

### Claim 15

A method for treatment of a FVIIa/TF related disorder in a human, which method comprises administering to said human a therapeutically effective amount of a human antibody, wherein said antibody immunoreacts with an epitope present on human TF.

### Claim 16 (depends on 1)

A method for treatment of a FVIIa/TF related disorder in a human, which comprises administering to said human a therapeutically effective amount of the antibody according to claim 1.

### Claim 17

A method for preparation of a human antibody, said method comprising:
a) Preparing human antibodies against human TF,
b) Testing said antibodies in (i) a TF-induced clot assay and selecting human antibody which inhibit clot formation in this assay with an IC50 value lower than the IC50 value of FFR-rFVIIa+1 nM, or (ii) a FXa generation assay and selecting human antibody which inhibit FXa generation with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 0.1 nM FVIIa), or (iii) a FVIIa/TF amidolytic assay and selecting human antibody which inhibit TF-induced FVIIa amidolytic activity, with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 10 nM FVIIa in the assay), or (iv) a FVIIa competition assay and selecting human antibody which compete with FVIIa binding, (v) a TF ELISA assay comprising TF and selecting human antibody which immunoreacts with human TF.

### Claim 18 (depends on 17)

The method accoding to claim 17, wherein the human antibodies against human TF are produced by a method comprising
a) immunizing a mammal with human TF, and
b) isolating antibodies produced by immunized mammal.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the mammal is a mouse.

### Claim 20 (depends on 17)

The method according to claim 17, which comprises testing antibodies in a TF-induced clot assay and selecting human antibody which inhibit clot formation in this assay with an IC50 value lower than the IC50 value of FFR-rFVIIa+1 nM.

### Claim 21 (depends on 17)

The method according to claim 17, which comprises testing antibodies in a FXa generation assay and selecting human antibody which inhibit FXa generation with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 0.1 nM FVIIa in the assay).

### Claim 22 (depends on 17)

The method according to claim 17, which comprises testing antibodies in a FVIIa/TF amidolytic assay and selecting human antibody which inhibit TF-induced FVIIa amidolytic activity, with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 10 nM FVIIa in the assay.

### Claim 23 (depends on 17)

The method according to claim 17, which comprises testing antibodies in a FVIIa competition assay and selecting human antibody which compete with FVIIa binding.

### Claim 24 (depends on 17)

The method according to claim 17, which comprises testing antibodies in a TF ELISA assay comprising TF and selecting human antibody which immunoreacts with human TF.

### Claim 25

A human antibody which immunoreacts with an epitope present on human TF and inhibits the binding of human coagulation factor VIIa to human TF, wherein said antibody is obtainable by a method comprising:
a) Preparation of human antibodies against human TF,
b) testing antibodies in a TF-induced clot assay and selecting human antibody which inhibit clot formation in this assay with an IC50 value lower than the IC50 value of FFR-rFVIIa+1 nM, such as lower than the IC50 value of FFR-rFVIIa+500 pM, preferably lower than the IC50 value of FFR-rFVIIa+200 pM, preferably lower than the IC50 value of FFR-rFVIIa+100 pM, such as lower than the IC50 value of FFR-rFVIIa+50 pM, preferably lower than the IC50 value of FFR-rFVIIa+10 pM, more preferably lower than the IC50 value of FFR-rFVIIa+5 pM, more preferably lower than the IC50 value of FFR-rFVIIa, or testing antibodies in a FXa generation assay and selecting human antibody which inhibit FXa generation with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 0.1 nM FVIIa in the assay), such as lower than the IC50 value of FFR-rFVIIa+10 nM, preferably lower than the IC50 value of FFR-rFVIIa+5 nM, preferably lower than the IC50 value of FFR-rFVIIa+1 nM, more preferably lower than the IC50 value of FFR-rFVIIa+0.1 nM, more preferably lower than the IC50 value of FFR-rFVIIa, or
testing antibodies in a FVIIa/TF amidolytic assay and selecting human antibody which inhibit TF-induced FVIIa amidolytic activity, with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 10 nM FVIIa), such as lower than the IC50 value of FFR-rFVIIa+40 nM, preferably lower than the IC50 value of FFR-rFVIIa+20 nM, preferably lower than the IC50 value of FFR-rFVIIa+10 nM, more preferably lower than the IC50 value of FFR-rFVIIa, or
testing antibodies in a FVIIa competition assay and selecting human antibody which compete with FVIIa binding, or
testing antibodies in a TF ELISA assay comprising TF and selecting human antibody which immunoreacts with human TF.

### Claim 26

A method for preparation of a human antibody, which method comprises
a) immunizing a mouse with human TF,
b) isolating antibody-producing cell from said immunized mouse and preparing of immortal cells that secrete human antibodies,
c) isolating culture medium from said immortal cells, wherein said culture medium comprises produced antibodies,
d) testing said antibodies in an indirect TF ELISA assay comprising TF in solution and selecting human antibodies that immunoreact with human TF in solution,
e) testing said antibodies in a FVIIa competition assay and selecting human antibodies which competes with FVIIa binding,
f) testing antibodies in a FVIIa/TF amidolytic assay and selecting human antibody which inhibit TF-induced FVIIa amidolytic activity, with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 10 nm FVIIa in the assay), such as lower than the IC50 value of FFR-rFVIIa+40 nM, preferably lower than the IC50 value of FFR-rFVIIa+20 nM, preferably lower than the IC50 value of FFR-rFVIIa+10 nM, more preferably lower than the IC50 value of FFR-rFVIIa,
g) testing antibodies in a FXa generation assay and selecting human antibody which inhibit FXa generation with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 0.1 nM FVIIa in the assay), such as lower than the IC50 value of FFR-rFVIIa+10 nM preferably lower than the IC50 value of FFR-rFVIIa+5 nM, preferably lower than the IC50 value of FFR-rFVIIa+1 nM, more preferably lower than the IC50 value of FFR-rFVIIa+0.1 nM, more preferably lower than the IC50 value of FFR-rFVIIa,
h) testing antibodies in a TF-induced clot assay and selecting human antibodies which inhibits clot formation in this assay with an IC50 value lower than the IC50 value of FFR-rFVIIa+1 nM, such as lower than the IC50 value of FFR-rFVIIa+500 pM, preferably lower than the IC50 value of FFR-rFVIIa+200 pM, preferably lower than the IC50 value of FFR-rFVIIa+100 pM, such as lower than the IC50 value of FFR-rFVIIa+50 pM, preferably lower than the IC50 value of FFR-rFVIIa+10 pM, more preferably lower than the IC50 value of FFR-rFVIIa+5 pM, more preferably lower than the IC50 value of FFR-rFVIIa,
i) selection and cultivation in a suitable culture medium of the immortal cell producing the selected antibody following step d-h,
j) isolation of selected antibody from culture medium of selected immortal cell.

### Claim 27 (depends on 26)

The method according to claim 26, wherein said method further comprises testing antibodies in a direct TF ELISA assay comprising immobilized TF and selecting human antibodies which immunoreacts with immobilized human TF.

### Claim 28 (depends on 26)

The method according to claim 26, wherein said method further comprises testing antibodies in a FXa generation assay on TF expressing cell and selecting human antibodies which inhibits FXa generation on TF expressing cell with an IC50 value lower than the IC50 value of FFR-rFVIIa+500 nM (using 1 nM FVIIa in the assay),

### Claim 29 (depends on 26)

The method according to claim 26, wherein said method further comprises testing antibodies in a whole cell TF binding assay and selecting human antibodies which competes with FVIIa binding to human TF expressed on the cell surface of whole cells.

### Claim 30 (depends on 26)

The method according to claim 26, wherein said method further comprises testing antibodies in a biosensor assay and selecting human antibodies with Kd for binding to human TF lower than 100 nM.

### Claim 31 (depends on 26)

The method according to claim 26, wherein said method further comprises testing antibodies in a MAPK signalling assay and selecting human antibodies which inhibit FVIIa-induced activation of the MAPK signalling.

### Claim 32 (depends on 26)

The method according to claim 26, wherein said method further comprises testing antibodies in an epitope mapping assay and selecting human antibodies which immunoreact with preferred epitopes on TF.

### Claim 33 (depends on 32)

The method according according to claim 32, wherein said preferred epitope comprises the residues Trp45, Lys46 and Tyr94.

### Claim 34 (depends on 26)

The method according to claim 26, wherein said immortal cell is a hybridoma cell.

### Claim 35

A human antibody which immunoreacts with an epitope present on human TF and inhibits the binding of human coagulation factor VIIa to human TF obtainable by a method comprising:
a) immunization of mouse with human TF,
b) isolation of antibody-producing cell from immunized mouse and preparation of immortal cells to secrete human antibodies,
c) isolation of culture medium from immortal cells comprising produced antibodies,
d) testing antibodies in an indirect TF ELISA assay comprising TF in solution and selecting human antibodies which immunoreacts with human TF in solution,
e) testing antibodies in a FVIIa competition assay and selecting human antibodies which competes with FVIIa binding,
f) testing antibodies in a FVIIa/TF amidolytic assay and selecting human antibody which inhibit TF-induced FVIIa amidolytic activity, with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 10 nM FVIIa in the assay), such as lower than the IC50 value of FFR-rFVIIa+40 nM, preferably lower than the IC50 value of FFR-rFVIIa+20 nM, preferably lower than the IC50 value of FFR-rFVIIa+10 nM, more preferably lower than the IC50 value of FFR-rFVIIa,
g) testing antibodies in a FXa generation assay and selecting human antibody which inhibit FXa generation with an IC50 value lower than the IC50 value of FFR-rFVIIa+100 nM (using 0.1 nM FVIIa in the assay), such as lower than the IC50 value of FFR-rFVIIa+10 nM, preferably lower than the IC50 value of FFR-rFVIIa+5 nM, preferably lower than the IC50 value of FFR-rFVIIa+1 nM, more preferably lower than the IC50 value of FFR-rFVIIa+0.1 nM, more preferably lower than the IC50 value of FFR-rFVIIa,
h) testing antibodies in a TF-induced clot assay and selecting human antibodies which inhibits clot formation in this assay with an IC50 value lower than the IC50 value of FFR-rFVIIa+1 nM, such as lower than the IC50 value of FFR-rFVIIa+500 pM, preferably lower than the IC50 value of FFR-rFVIIa+200 pM, preferably lower than the IC50 value of FFR-rFVIIa+100 pM, such as lower than the IC50 value of FFR-rFVIIa+50 pM, preferably lower than the IC50 value of FFR-rFVIIa+10 pM, more preferably lower than the IC50 value of FFR-rFVIIa+5 pM, more preferably lower than the IC50 value of FFR-rFVIIa,
i) selection and cultivation in a suitable culture medium of the immortal cell producing the selected antibody following step d-h,
j) isolation of selected antibody from culture medium of selected immortal cell.

### Claim 36 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34)

A human antibody which immunoreacts with an epitope present on human TF and inhibits the binding of human coagulation factor VIIa to human TF produced by a method according to any one of the claims 26-34.

### Claim 37

A cell producing human antibody which immunoreacts with an epitope present on human TF and inhibits the binding of human coagulation factor VIIa to human TF.

### Claim 38 (depends on 37)

The cell according to claim 37, wherein said cell is an isolated lymphoid cell.

### Claim 39 (depends on 37)

The cell according to claim 37, wherein said cell is isolated from a mouse.

### Claim 40 (depends on 37)

The cell according to claim 37, wherein said cell is a hybridoma cell.

### Claim 41 (depends on 40)

The cell according to claim 40, wherein said hybridoma cell is obtained by fusion of an antibody-producing lymphoid cell with an immortal cell to provide an antibody-producing hybridoma cell.

### Claim 42 (depends on 37)

The cell according to claim 37, wherein said antibody inhibits the binding of human coagulation factor VIIa to human TF.

### Claim 43 (depends on 37)

The cell according to claim 37, wherein said antibody immunoreacts with a 3-dimensional surface involving all the residues Trp45, Lys46 and Tyr94.

### Claim 44 (depends on 37, 38, 39, 40, 41, 42, 43)

The cell according to any one of the claims 37-43, wherein said antibody is a Fab fragment.

### Claim 45 (depends on 37, 38, 39, 40, 41, 42, 43, 44)

The cell according to any one of the claims 37-44, wherein said antibody is a F(ab)2 fragment.

### Claim 46 (depends on 37, 38, 39, 40, 41, 42, 43, 44)

The cell according to any one of the claims 37-44, wherein said antibody is a F(ab′)2 fragment.

### Claim 47 (depends on 37, 38, 39, 40, 41, 42, 43, 44)

The cell according to any one of the claims 37-44, wherein said antibody is a scFv fragment.

### Claim 48 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The cell according to any one of the claims 37-47, wherein said antibody has a Kd for binding to human TF within the range of 10−15-10−5 M.

### Claim 49 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The cell according to any one of the claims 37-48, wherein said antibody has a Kd for binding to human TF within the range of 10−15-10−10 M.
